After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene (CELG) or Gilead (GILD) .

Cramer addressed these stocks on Thursday's edition of CNBC's Mad Money.

Meanwhile, President Trump is set to deliver a speech on drug pricing on Friday. 

For exclusive investing insight from Jim Cramer, get 24/7 access to Jim's charitable trust portfolio with a free trial to Action Alerts PLUS!

More from Video

Why Big Mergers Are Still Happening Even With Stocks at Record Highs

Why Big Mergers Are Still Happening Even With Stocks at Record Highs

Market of the Week

Market of the Week

We Are In a Rising Interest Rate Cycle, Says Legendary Technician

We Are In a Rising Interest Rate Cycle, Says Legendary Technician

Here Is Why Some Investors View Airbnb as an Asset Class

Here Is Why Some Investors View Airbnb as an Asset Class

Everything You Need to Know About Closed-End Funds to Boost Your Portfolio

Everything You Need to Know About Closed-End Funds to Boost Your Portfolio